** Shares of Orthocell OCC.AX rise 15.4% to A$1.500, their highest levels since Jan 6
** The regenerative medicine firm says that it plans to enter key markets such as Canada and Thailand, among others, in CY2025
** Orthocell recently submitted its USFDA regulatory application for the clearance to distribute its nerve drug Remplir in the $1.6 bln (A$2.55 bln) U.S. market commercially
** Co expects approval in March/April 2025
** About 3.4 mln shares trade hands, 1.9 times the 30-day average of 1.8 mln
** Stock rose 230.5% in 2024
(1 Australian dollar = $0.6266)
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.